Kepler Capital Markets set a GBX 5,200 ($67.74) price objective on AstraZeneca plc (LON:AZN) in a research report report published on Friday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other equities research analysts also recently issued reports on AZN. UBS AG set a GBX 5,150 ($67.09) price target on AstraZeneca plc and gave the stock a neutral rating in a report on Wednesday, April 5th. Credit Suisse Group decreased their price target on AstraZeneca plc from GBX 5,000 ($65.14) to GBX 4,700 ($61.23) and set a neutral rating for the company in a report on Friday. Citigroup Inc. reiterated a buy rating and set a GBX 6,000 ($78.17) price target on shares of AstraZeneca plc in a report on Friday. J P Morgan Chase & Co reiterated a neutral rating on shares of AstraZeneca plc in a report on Friday, July 21st. Finally, Deutsche Bank AG reiterated a buy rating and set a GBX 5,700 ($74.26) price target on shares of AstraZeneca plc in a report on Friday. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of GBX 5,085.05 ($66.25).
ILLEGAL ACTIVITY NOTICE: “Kepler Capital Markets Analysts Give AstraZeneca plc (LON:AZN) a GBX 5,200 Price Target” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://theolympiareport.com/2017/07/31/kepler-capital-markets-analysts-give-astrazeneca-plc-lonazn-a-gbx-5200-price-target.html.
The business also recently disclosed a dividend, which will be paid on Monday, September 11th. Investors of record on Thursday, August 10th will be issued a dividend of GBX 68.90 ($0.90) per share. The ex-dividend date is Thursday, August 10th. This represents a yield of 1.35%.
In related news, insider Nazneen Rahman acquired 39 shares of the company’s stock in a transaction that occurred on Thursday, July 27th. The shares were acquired at an average price of GBX 4,370 ($56.93) per share, with a total value of £1,704.30 ($2,220.30).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AstraZeneca plc and related companies with Analyst Ratings Network’s FREE daily email newsletter.